PDS5A and TOP2B cooperate for chromatin recruitment via CTCF

This study reveals that PDS5A and TOP2B cooperatively recruit each other to CTCF-bound chromatin sites via a novel CTCF interaction region to maintain genome organization and regulate gene expression, with dysregulation of this axis contributing to glioma heterogeneity and influencing sensitivity to TOP2-targeted cancer therapies.

The Gist

The Big Picture: Organizing the Library of Life

Imagine your DNA is a massive, chaotic library containing every instruction manual needed to build and run a human body. To keep this library organized, the long strands of DNA are folded into tight loops and sections, much like books on a shelf. These loops are held in place by "bookends" called CTCF.

Inside these loops, a machine called Cohesin acts like a motor, pulling the DNA strands together to form the loops. But for the loops to stay the right size and shape, they need a supervisor. That supervisor is a protein called PDS5A.

However, there's a problem: sometimes the DNA gets twisted and knotted (like a tangled headphone cord) when the library is being read. To fix this, a "scissor-wielding" enzyme called TOP2B cuts the DNA, untangles it, and sews it back together.

The Big Discovery: This paper found out that PDS5A (the supervisor) and TOP2B (the scissor-wielder) are actually best friends who work together. They don't just hang out; they need each other to get to the right spot on the DNA shelf.

---

The Story: How They Meet and Work

1. The "Trap" Experiment

The scientists wanted to see how these proteins interact. They used a drug called Etoposide (a common cancer drug) that acts like a "trap."

• The Analogy: Imagine TOP2B is a construction worker cutting a wire to fix a knot. The drug traps the worker while the wire is cut but before it's re-joined.
• The Result: When they trapped TOP2B on the DNA, they noticed that PDS5A suddenly showed up in huge numbers at those exact spots. It was as if the trapped worker waved a flag, and PDS5A came running to help.

2. The Secret Handshake (The CTCF Connection)

The scientists realized that PDS5A and TOP2B don't just wander onto the DNA randomly. They need an invitation from the "bookend," CTCF.

• The Discovery: They found a specific "handshake zone" on CTCF (a tiny section of the protein, amino acids 95-116).
• The Analogy: Think of CTCF as a bouncer at a club. PDS5A and TOP2B are VIPs. To get in, they need to show a specific ID card (the 95-116 region). If you cut off that ID card (by deleting those amino acids), the bouncer (CTCF) can't let the VIPs (PDS5A and TOP2B) in together.
• The Consequence: Without this handshake, the DNA loops fall apart, and the library gets messy. Genes that should be quiet start shouting, and genes that should be loud go silent.

3. The Brain Tumor Connection (Gliomas)

The researchers then looked at brain tumors called Gliomas (specifically Glioblastomas). These tumors are notorious for being unpredictable; some patients respond well to treatment, while others don't.

• The Correlation: They found that in these tumors, the levels of PDS5A and TOP2B rise and fall together. If a tumor has a lot of TOP2B, it usually has a lot of PDS5A.
• The Drug Sensitivity: Here is the kicker: The amount of PDS5A determines whether the tumor cells will die when hit with TOP2 drugs (like Etoposide).
  • High PDS5A: The "scissors" (TOP2B) are trapped effectively, and the DNA gets cut up, killing the cancer cell.
  • Low PDS5A: The "scissors" can't stay in the right spot. The cancer cell survives the attack.

Why This Matters (The Takeaway)

This paper solves a mystery about how our genome stays organized and explains why brain cancer treatments sometimes fail.

1. The Mechanism: It turns out that PDS5A and TOP2B are a team. TOP2B's activity helps recruit PDS5A to the DNA, and PDS5A helps keep TOP2B in the right place. They rely on a specific handshake with CTCF to do this.
2. The Cancer Link: In brain tumors, if PDS5A is missing or low, the TOP2B enzyme goes to the wrong places or doesn't stay put. This makes the tumor resistant to drugs that are supposed to kill it by cutting DNA.
3. The Future: This suggests that doctors might be able to predict if a patient will respond to standard cancer drugs just by checking how much PDS5A is in their tumor. If PDS5A is low, they might need a different kind of treatment.

In a nutshell: PDS5A and TOP2B are a dynamic duo that keeps our DNA organized. They need a specific handshake with a protein named CTCF to get to work. In brain cancer, if this partnership breaks down, the cancer cells become immune to the drugs we use to cut their DNA, making the tumor harder to treat.

Technical Summary

1. Problem Statement

The three-dimensional organization of the mammalian genome, specifically the formation of chromatin loops and Topologically Associating Domains (TADs), is critical for gene regulation. These structures are formed by the cohesin complex, which extrudes DNA loops until stalled by insulator proteins like CTCF. While the roles of cohesin and CTCF are well-established, the mechanisms governing the recruitment of regulatory subunits (PDS5A/B) and topoisomerases (TOP2A/B) to these chromatin boundaries remain poorly understood.

• Specific Gap: TOP2B is known to resolve DNA topological stress (supercoiling) generated during transcription and loop extrusion, and it co-localizes with CTCF and cohesin. However, how TOP2B is recruited to chromatin and how it interacts with PDS5A to maintain genome architecture is unclear.
• Clinical Relevance: TOP2 enzymes are targets for common cancer drugs (e.g., Etoposide, Doxorubicin). Glioblastomas (GBM) exhibit high heterogeneity and variable responses to these therapies. Understanding the recruitment dynamics of TOP2B could explain this resistance and inform therapeutic strategies.

2. Methodology

The study employed a multi-faceted approach combining molecular biology, genomics, and cancer cell models:

• Cell Models:
  • Mouse Embryonic Stem Cells (mESCs): Used for genetic manipulation, including a CTCF-degron system (CTCF-GFP-AID-Tir1) to acutely degrade endogenous CTCF.
  • Differentiated Motor Neurons (MNs): Derived from mESCs to isolate TOP2B activity (as TOP2A levels drop upon differentiation).
  • Glioma Cell Lines: Specifically BT142 (IDH1-mutant) and U87MG, used to study human tumor contexts.
• Pharmacological Trapping: Treatment with Etoposide (ETO), a TOP2 poison that traps the enzyme-DNA cleavage complex, was used to stabilize "active" TOP2 on chromatin for detection.
• Genomic Assays:
  • ChIP-seq: To map genome-wide occupancy of CTCF, PDS5A, PDS5B, TOP2B, and RAD21 under various conditions (DMSO vs. ETO, WT vs. Mutant).
  • Micro-C: High-resolution chromatin conformation capture to analyze loop structures and TAD integrity.
  • RNA-seq: To assess global gene expression changes.
• Biochemical & Structural Analysis:
  • Co-Immunoprecipitation (IP): To verify protein-protein interactions in nuclear extracts.
  • Rescue Experiments: Re-introduction of wild-type (WT) or mutant CTCF (deleting specific N-terminal regions) into CTCF-degron cells.
  • Electrophoretic Mobility Shift Assay (EMSA): Using recombinant proteins to test in vitro binding of CTCF, PDS5A, and TOP2B to DNA probes.
  • AlphaFold2: Used to predict protein-protein interaction interfaces.
• Clinical Correlation: Analysis of public datasets (GlioVis, cBioPortal) and immunohistochemistry (IHC) on human glioma tissue arrays to correlate PDS5A and TOP2B expression levels.

3. Key Contributions

• Discovery of a Novel Interaction Interface: Identification of a previously unknown interaction region within the N-terminal domain of CTCF (amino acids 95–116) that is essential for the cooperative recruitment of PDS5A and TOP2B.
• Mechanism of Recruitment: Elucidation of a reciprocal relationship where active TOP2B enzymatic activity (or the resulting DNA double-strand breaks) promotes the enrichment of PDS5A at CTCF-bound sites. Conversely, PDS5A is required for stable TOP2B occupancy.
• Clinical Insight: Demonstration that PDS5A levels mediate sensitivity to TOP2-targeting cancer drugs in glioma cells, providing a mechanistic basis for the heterogeneity observed in GBM treatment responses.

4. Key Results

A. Interaction and Recruitment Dynamics

• CTCF-PDS5A-TOP2B Complex: Co-IPs confirmed that CTCF, PDS5A/B, and TOP2B form a complex in both mouse and human cells. Notably, TOP2B (but not TOP2A) interacts with CTCF.
• TOP2B Activity Enriches PDS5A: Treatment with Etoposide (trapping active TOP2B) significantly increased PDS5A chromatin occupancy genome-wide in mESCs and MNs. This enrichment was CTCF-dependent; degrading CTCF abolished the ETO-induced PDS5A gain.
• Specificity: The enrichment was specific to PDS5A; PDS5B levels remained unchanged by ETO treatment.

B. The Novel CTCF Interaction Region (aa 95–116)

• Mapping: AlphaFold predictions and rescue experiments identified two critical N-terminal regions of CTCF for PDS5A interaction: the known region (aa 13–33) and a novel region (aa 95–116).
• Functional Impact of Mutants:
  • CTCF-Δ13-33: Showed weak PDS5A enrichment upon ETO treatment.
  • CTCF-Δ95-116: Completely failed to recruit PDS5A upon ETO treatment.
  • In Vitro Validation: EMSA assays with recombinant proteins confirmed that the CTCF-Δ95-116 mutant could bind DNA but failed to recruit the PDS5A-TOP2B complex, whereas WT CTCF successfully did so.
• Genome Organization: Deletion of the 95–116 region (CTCF-MUT2) led to a reduction in chromatin loops (measured by Micro-C APA) and altered gene expression (1,354 differentially expressed genes), affecting developmental and metabolic pathways.

C. Relevance to Glioma and Drug Sensitivity

• Correlation in Tumors: In human glioma samples (tissue arrays and RNA-seq data), PDS5A and TOP2B expression levels are strongly correlated (Pearson r ≈ 0.7).
• Reciprocal Regulation in Glioma: In BT142 glioma cells:
  • PDS5A Knockdown (KD): Led to a significant reduction in TOP2B occupancy at chromatin boundaries, particularly at CTCF sites.
  • Gene Expression: PDS5A KD altered gene expression patterns similar to those seen with TOP2 enzymatic inhibition (ICRF-193).
• Drug Sensitivity: PDS5A KD rendered BT142 cells resistant to TOP2-targeting drugs (Etoposide and Doxorubicin). Cells with reduced PDS5A survived drug treatment better than controls, suggesting that PDS5A-mediated recruitment of TOP2B is a prerequisite for the efficacy of these drugs.

5. Significance

• Mechanistic Clarity: The study resolves a long-standing question regarding how TOP2B is recruited to chromatin, proposing a model where TOP2B enzymatic activity and PDS5A mutually reinforce each other's localization at CTCF-defined boundaries.
• Structural Biology: The identification of the CTCF 95–116aa motif as a critical hub for the cohesin-TOP2B axis provides a new target for understanding genome folding defects.
• Therapeutic Implications: The findings explain the heterogeneity in glioma responses to TOP2 inhibitors. High PDS5A expression correlates with high TOP2B recruitment and potentially higher drug sensitivity. Conversely, low PDS5A may lead to TOP2B mislocalization and drug resistance. This suggests that PDS5A levels could serve as a biomarker for predicting response to TOP2-targeting chemotherapy in glioma patients.
• Cancer Genomics: By linking the mechanics of loop extrusion and topological stress resolution to drug efficacy, the paper offers a new perspective on how chromatin architecture influences cancer treatment outcomes.